Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting
- Majority (74%) of patients with non-ambulatory Type 2 and Type 3 SMA achieved a clinical improvement in Hammersmith Functional Motor Scale Expanded (HFMSE) after 12 months
- New exploratory analysis of TOPAZ data found no correlation between duration of prior nusinersen treatment and increases in HFMSE, adding support that observed motor function improvements may be attributable to apitegromab
- Company to host KOL event and panel discussion on apitegromab’s therapeutic potential in patients with SMA on
“The TOPAZ results show that apitegromab has promising potential to benefit the large portion of individuals with SMA who still manifest muscle weakness,” said
SMA remains a devastating and debilitating disease despite the utilization of SMN upregulators that prevent further motor neuron deterioration. A muscle-directed approach such as apitegromab, a selective inhibitor of myostatin activation, has the potential to complement SMN upregulators and address motor function impairments in patients with SMA. Scholar Rock’s TOPAZ Phase 2 trial (NCT03921528) evaluated apitegromab across a broad age range (2-21 years) of patients with Type 2 and 3 SMA. With the exception of some ambulatory patients who received apitegromab as a monotherapy, patients enrolled in TOPAZ were receiving chronic maintenance doses of nusinersen. Both non-ambulatory cohorts had received more than 5.0 mean maintenance doses or approximately 2 years of treatment at baseline. Clinical data from the CHERISH and SHINE studies of nusinersen offer background insights into this patient population.1 These studies observed that nusinersen-treated patients primarily experienced stabilization or only slight increases in HFMSE scores beyond the initial 15-month treatment period.2 In addition, even in the initial 15-month treatment period, patients who initiated nusinersen treatment age ≥5 on average experienced declines in HFMSE and rarely attained a ≥3-point increase in HFMSE in a 12-month timeframe.3
Results following 12-months of treatment with apitegromab added to background nusinersen therapy, in the TOPAZ trial, included:
- Majority (74%, 23/31) of non-ambulatory patients showed a clinical improvement (≥1-point increase) in Hammersmith Functional Motor Scale Expanded (HFMSE).
In the non-ambulatory cohort of patients (mean age 3.8) on background nusinersen started earlier in life (<5 years of age), treatment with apitegromab 20 mg/kg led to sizeable increases in HFMSE.
- Mean increase from baseline was +7.1 points.
- 88% (7/8) of patients improved (attained a ≥1-point increase).
- 63% (5/8) of patients attained a ≥5-point increase.
- 38% (3/8) of patients attained a >10-point increase.
- Patients had received approximately two years of prior nusinersen treatment at the time of enrollment (5.4 mean maintenance doses) and were in the chronic maintenance phase of nusinersen therapy during the TOPAZ trial.
In the non-ambulatory cohort of patients (mean age 11.7) on background nusinersen started later in life (≥5 years of age), treatment with apitegromab 20 mg/kg led to an increase in HFMSE, contrasting with declines experienced on average by this patient population without treatment.
- Mean increase from baseline was +0.6 points by intent-to-treat analysis and +1.2 points by per-protocol analysis.
- 64% (9/14) of patients improved (attained a ≥1-point increase).
- 29% (4/14) of patients attained a ≥3-point increase.
- Patients had received approximately two years of prior nusinersen treatment at the time of enrollment (5.1 mean maintenance doses) and were in the chronic maintenance phase of nusinersen therapy during the TOPAZ trial.
- A post-hoc analysis across all non-ambulatory patients showed no correlation between change in HFMSE score at 12 months and duration of prior nusinersen therapy, providing further evidence that improvements in motor function may be attributed to apitegromab.
WHO Motor Development Milestones, a high bar assessment representing major functional achievements, were gained by seven of 35 non-ambulatory patients treated with apitegromab and nusinersen, including three patients who initiated background nusinersen therapy later in life (≥5 years of age).
- Five patients achieved one new WHO motor milestone, including one patient gaining the ability to walk independently and one patient gaining the ability to stand independently.
- One patient achieved two new WHO motor milestones (hands and knees crawling and standing with assistance).
- One patient achieved three new WHO motor milestones (hands and knees crawling, standing with assistance, and walking with assistance).
- The five most frequently reported treatment-emergent adverse events (AEs) included headache, pyrexia, upper respiratory tract infection, cough, and nasopharyngitis. Incidence and severity of AEs were consistent with the underlying patient population and background therapy.
- Data from additional exploratory endpoints are being analyzed and will be presented in the future, such as at medical and scientific conferences.
A randomized, double-blind, placebo-controlled Phase 3 trial is anticipated to initiate by the end of 2021 and is expected to evaluate apitegromab as an add-on to nusinersen or risdiplam in patients with non-ambulatory Type 2 and Type 3 SMA.
“We are delighted to share the TOPAZ trial results at the annual Cure SMA conference, including new exploratory analyses that further highlight apitegromab’s transformative potential to improve motor function in patients with SMA,” said
Details for the virtual Cure SMA oral presentation are as follows:
- Title: TOPAZ: A Phase 2 Study to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy (Type 2 and Type 3 SMA): Topline Results
Thomas Crawford, M.D. Co-Director, Muscular Dystrophy Association Clinicand Professor of Neurology and Pediatrics, Johns Hopkins Medicine(Lead TOPAZ Principal Investigator)
Clinical Drug Development Session: Virtual oral presentation on
June 11, 2021at 2:00pm CST
1This information from third-party studies is provided for background purposes only and is not intended to convey or imply a comparison to the TOPAZ clinical trial results.
2 Source: “Longer-term treatment with nusinersen: results in later-onset spinal muscular atrophy from the SHINE study” P.257,
3 Source: Mercuri E, et.al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625-635.
Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA). Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans.
Spinal muscular atrophy (SMA) is a rare, and often fatal, genetic disorder that typically manifests in young children. An estimated 30,000 to 35,000 patients are afflicted with SMA in
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s expectations regarding its growth, strategy, progress and timing of its clinical trials and the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended